Introduction and Objective: CGM is the standard of care for insulin-treated patients with T2D, however, most such patients are managed in primary care settings where CGM use has historically been low. To our knowledge, national CGM prescribing rates in primary care have not previously been reported. We aimed to describe CGM prescribing trends and identify priority targets for future implementation efforts in primary care. Methods: We used data from Epic Cosmos, representing 300M U.S. residents, to analyze CGM prescription rates in primary care from 2020-2025 for adults with T2D treated with insulin and excluded patients with endocrinology visits. We examined temporal trends and differences in rates across demographics groups using linear models. Results: Among 5.4M eligible adults (mean age 67±15y, 48% F, 11% Hispanic, 18% Black, 76% publicly insured), 947,568 (17%) had ever been prescribed CGM in primary care. Monthly CGM uptake increased from 6% in 2020 to 33% in 2025 (p-trend 0.001), but remained lowest among older adults, publicly insured, and Spanish-speaking (Figure). Conclusion: CGM prescribing in U.S. primary care has increased substantially among insulin-treated adults, signaling adoption beyond specialty care. However, uptake continues to lag among older, publicly insured, and non-English-speaking patients. Targeted, equity-focused implementation strategies are urgently needed to ensure CGM benefit reaches all insulin-treated adults with T2D and to establish national benchmarks. Disclosure J. Milosavljevic: None. L. Rasquin Leon: None. K.N. Diaz: None. S. Rikin: None. S. Agarwal: None. Funding American Diabetes Association (7-25-JDFPC-0403)
Milosavljevic et al. (Fri,) studied this question.